Recursion Pharmaceuticals, Inc.
NASDAQ:RXRXBiotechnology
+$0.04 today
- Market cap
- $1.76B
- Beta
- 1.00
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$1.06
Volume 41.13M
Average 15.60M
RXRX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Recursion Pharmaceuticals, Inc.NASDAQ: RXRX
Retained Earnings · Q2 FY2026 · quarter ended Jun 2026
Retained earnings remains negative
Q2 FY2026 retained earnings was -$2.32B, compared with -$1.81B a year earlier.
Context
- Retained earnings amounted to 191.7% of total assets at the end of Q2 FY2026, up 53.0 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -28.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (2.08B) USD
- Year-over-year change
- -45.0%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.08B) | -45.0% |
| FY2024 | 2024-12-31 | (1.43B) | -47.9% |
| FY2023 | 2023-12-31 | (967.62M) | -51.3% |
| FY2022 | 2022-12-31 | (639.56M) | -59.9% |
| FY2021 | 2021-12-31 | (400.08M) | — |
Retained Earnings vs competitors
How RXRX compares with its peers on the latest reported figures
- RXRX's Jun 2026 retained earnings of -$2.32B is the lowest of the 4 companies compared; the peer median is -$2.17B.
- Its year-over-year change of -28.7% is the 3rd highest of 4, against a peer median of -28.5%.
- Retained earnings amounts to 191.7% of total assets for RXRX, versus a peer median of 199.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$513.76M | -31.3% | — | 122.4% | |
| Jun 2026 | -$2.17B | -15.2% | — | 224.5% | |
| Jun 2026 | -$2.31B | -28.5% | — | 199.3% | |
| Jun 2026 | -$2.32B | -28.7% | — | 191.7% | |
| Peer median (excluding RXRX) | -$2.17B | -28.5% | — | 199.3% | |
Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 285.12M | 549.91M | 391.57M | 594.35M | 743.29M |
| Short-term Investments | 231.45M | 0 | 0 | 0 | 0 |
| Net Receivables | 9.09M | 2.75M | 3.09M | 49.17M | 24.65M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 9.07M | 17.15M | 43.48M | 70.75M | 33.16M |
| Total Current Assets | 534.72M | 569.81M | 438.14M | 714.27M | 812.85M |
| Property, Plant & Equipment (Net) | 64.73M | 121.45M | 120.17M | 233.21M | 169.48M |
| Goodwill | 801K | 801K | 52.06M | 148.87M | 162.16M |
| Intangible Assets | 1.39M | 1.31M | 36.44M | 335.86M | 309.9M |
| Long-term Investments | 0 | 0 | 0 | 5.63M | 0 |
| Tax Assets | 0 | 0 | 0 | 1.93M | 957K |
| Other Non-current Assets | 8.72M | 7.92M | 6.89M | 8.83M | 18.79M |
| Total Non-current Assets | 75.63M | 131.47M | 215.56M | 734.33M | 661.29M |
| Total Assets | 610.35M | 701.29M | 653.7M | 1.45B | 1.47B |
| Account Payables | 2.82M | 4.59M | 3.95M | 21.61M | 18.12M |
| Short-term Debt | 90K | 97K | 41K | 8.43M | 9.09M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 10M | 56.73M | 36.43M | 61.77M | 37.61M |
| Other Current Liabilities | 11.74M | 20.43M | 23.75M | 50.85M | 31.77M |
| Total Current Liabilities | 46.66M | 100.27M | 93.17M | 187.47M | 147.71M |
| Long-term Debt | 633K | 536K | 1.1M | 19.02M | 9.56M |
| Deferred Tax Liabilities | 0 | 0 | 1.34M | 16.58M | 23.26M |
| Deferred Revenue (Non-current) | 6.67M | 70.26M | 51.24M | 118.77M | 114.01M |
| Other Non-current Liabilities | 4.11M | 0 | 0 | 4.73M | 2.08M |
| Total Non-current Liabilities | 20.75M | 115.22M | 97.09M | 226.34M | 195.56M |
| Total Liabilities | 67.41M | 215.48M | 190.26M | 413.82M | 343.27M |
| Common Stock | 2K | 2K | 2K | 4K | 5K |
| Retained Earnings | (400.08M) | (639.56M) | (967.62M) | (1.43B) | (2.08B) |
| Accumulated OCI | (126K) | 0 | 0 | (7.64M) | 36.72M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 542.94M | 485.81M | 463.44M | 1.03B | 1.13B |
| Total Debt | 11.48M | 51.01M | 50.67M | 108.49M | 77.97M |
| Net Debt | (273.64M) | (498.91M) | (340.89M) | (485.86M) | (665.33M) |
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
Intrinsic Alpha fair value
Locked
Current Price
$2.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.